Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies
항암치료를 받는 환자의 코로나19 백신접종에 대한 항체 및 T세포 반응
Article
Published on
Journal: Journal for immunotherapy of cancer [Category] COVID19(2023년), MERS, SARS, 바이오마커, 변종, 진단, 치료기술, 치료제,
Journal: Journal for immunotherapy of cancer [Category] COVID19(2023년), MERS, SARS, 바이오마커, 변종, 진단, 치료기술, 치료제,
[키워드] active treatment
adrenal crisis
Adrenal insufficiency
Affect
Anti-CD20 antibodies
Anti-CD20 antibody
Anti-viral
antibodies
antibody
antibody formation
Antibody titer
Antibody titers
Anticancer therapy
B cells
B-cell
B.1.617.2
blockade
Cancer
CD4
CD8
Cell
cellular
Chemoimmunotherapy
Chemotherapy
Corticosteroids
COVID-19
COVID-19 infection
COVID-19 infections
COVID-19 vaccination
COVID-19 vaccinations
COVID-19 vaccine trials
cross-reactive
cytokine
detectable
develop
dose
doses
effector cells
Endocrine
expressed
follicular
generate
healthy donor
healthy donors
helper cells
Humoral response
hypoadrenalism
Hypothesis
IgG antibody titer
immune
Immunocompromised
immunogenic
immunogenicity
immunogenicity, vaccine
Immunotherapy
intracellular cytokine staining
Lymphocytes
mRNA vaccine
Multiple myeloma
Myeloma
n=36
no differences
oncology patients
Participants
Patient
Patients with cancer
PD-1
peptide
peptides
Phase 3
profile
Prophylactic
RBD
reactivity
receiving
Receptor binding domain
Safe
seronegative
seronegative patient
Side effect
solid tumors
spike
Spike protein
steroid
Steroids
Stress
symptomatic
T cell
T cell response
T cell responses
T cells
T follicular helper cells
T-lymphocytes
targeted therapy
the SARS-CoV-2
therapy
Treatment
treatment groups
tumors
Two patient
two patients
vaccination
Vaccinations
Vaccine
variant spike
was measured
were assessed
were excluded
wild-type
WT spike
[DOI] 10.1136/jitc-2022-004766 PMC 바로가기 [Article Type] Article
[DOI] 10.1136/jitc-2022-004766 PMC 바로가기 [Article Type] Article